Amendments to the Claims:

This listing of claims replaces all prior listings and versions of claims in this application.

1. (Previously presented) A method of inhibiting proliferation of a target cell, comprising contacting the cell with a GPC5 antagonist selected from the group consisting of antisense RNA, antisense DNA and dsRNA, which comprises a nucleic acid sequence complementary to the sequence of GPC5 mRNA or pre-mRNA.

2. (Original) A method according to claim 1 wherein the target cell inappropriately expresses or overexpresses GPC5.

3. (Previously presented) A method according to claim 1 wherein the cell inappropriately expresses or overexpresses WT1.

4. (Previously presented) A method according to claim 1 wherein the cell is a cancer cell.

5. (Original) A method according to claim 4 wherein the cancer is rhabdomyosarcoma, lymphoma, non-small cell lung cancer, bladder cancer, breast cancer, prostate cancer, a neuroglial tumour, squamous cell carcinoma of the head and neck, leukemia, leiomyosarcoma, liposarcoma, malignant fibrous histocytoma of bone or soft tissues, melanoma, mesothelioma, thyroid cancer, lung cancer, testicular cancer or ovarian cancer.

6. (Original) A method according to any one of claims 1 to 5 wherein the cell does not carry a chromosomal amplicon at 13q31.

7-12. (Canceled)

13. (Previously presented) A method according to claim 1 wherein the GPC5 antagonist inhibits expression of functional GPC5 at the cell surface.

14. (Canceled)

15. (Currently amended) A method according to claim ~~14~~ 1 wherein the CPC5 antagonist is selected from the group consisting of antisense RNA, RNAi and siRNA.

16-17. (Canceled)

18. (Currently amended) A method according to ~~any one of claims 13 to 15~~claim 1 further comprising contacting the cell with a therapeutic agent.

19. (Original) A method according to claim 18 wherein the GPC5 antagonist increases the sensitivity of the cell to the therapeutic agent.

20-41. (Canceled)